GenomOncology announced an integrated end-to-end workflow using PacBio’s long-read whole-genome sequencing technology for oncology on July 30, 2026 [1].

This development aims to streamline how clinical laboratories process complex genetic data. By automating the transition from raw sequencing to final reporting, the system intends to reduce the manual burden on pathologists while increasing the precision of cancer diagnostics.

The new solution pairs PacBio HiFi WGS with the GenomOncology Pathology Workbench [1]. This combination allows clinical labs to produce genomic reports that are configurable, and aligned with reimbursement requirements across various tumor types [1].

GenomOncology is a precision oncology software company that specializes in the interpretation and reporting of genomic data [2]. The company, headquartered in Cleveland, is designing the workflow to support labs globally in managing somatic whole-genome sequencing [1], [2].

"Combined sample-to-report solution pairs PacBio HiFi WGS with GenomOncology Pathology Workbench to support clinical labs in delivering configurable, reimbursement-aligned genomic reports across tumor types," GenomOncology said [1].

The integration focuses on the ability to handle somatic whole-genome sequencing (WGS) within a single, unified pipeline [1]. This approach seeks to bridge the gap between the high-resolution data provided by long-read sequencing and the practical needs of clinical reimbursement and reporting [1].

GenomOncology said the workflow provides a comprehensive path for somatic WGS in oncology [2].

“Combined sample-to-report solution pairs PacBio HiFi WGS with GenomOncology Pathology Workbench”

The integration of long-read sequencing with a specialized reporting workbench addresses a major bottleneck in precision medicine: the translation of massive genomic datasets into actionable clinical reports. By aligning these reports with reimbursement standards, GenomOncology is attempting to make high-fidelity whole-genome sequencing economically viable for standard clinical use rather than limiting it to research environments.